Core Insights - Harrison Global Holdings Inc. has outlined its growth strategy and recent developments during a successful investor webinar, emphasizing multi-sector expansion and financial initiatives [1][2] Strategic Partnerships - The company has made strategic acquisitions, including Miss Korea, Inc., Pokémon Center Korea, and Bucket Studios, and announced a partnership with Graves Inc., an AI-powered entertainment platform [2][3] Financial Updates - Management provided updates on the second tranche of PIPE financing and indicated a strong profitability outlook, with the upcoming quarterly earnings report expected between February and March [3][9] Gold Mine Development - A Strategic Business Agreement with HL Co., Ltd. was announced to develop the Suryun-myeon gold mine, which is estimated to contain approximately 1,188,000 tons of ore at 14g/ton, equivalent to 16.63 tons of gold [4][5] Share Repurchase Program - The Board of Directors approved a Share Repurchase Program allowing the company to repurchase up to US$10 million of its shares if the market price is below US$1.00 post-reverse-split [6][7][8] Long-term Growth Strategy - The leadership team emphasized a diversified growth strategy across entertainment, technology, biotechnology, and real-world asset development, aimed at creating enduring shareholder value [9]

Group 1 - Septerna, Inc. reported a 3Q25 GAAP EPS of $0.18, indicating a significant improvement from previous losses, primarily driven by partnership-related revenue [1] - The company has a focus on biotechnology, emphasizing innovative approaches in drug development, including novel mechanisms of action and first-in-class therapies [1] - The analysis aims to evaluate the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1]

Summary of the Conference Call on China Healthcare Sector Industry Overview - The conference call focused on the **China healthcare sector**, highlighting recent weaknesses and potential opportunities for 2026 [2][5][6]. Core Insights and Arguments - **Current Market Performance**: The Hang Seng Healthcare Index (HSHCI) has declined by **3.1%**, while the Hang Seng Index fell by **1.6%**. The HSHCI has dropped approximately **17%** from its year-to-date high in early October, with some small and mid-cap stocks down around **30%** [2][5]. - **Valuation Outlook**: Despite the current weakness, the fundamentals of the sector remain intact, and valuations are becoming more attractive, suggesting a potential rebound in 2026 [2][5][6]. - **Investment Recommendations**: - **Biotech**: Innovent and Kelun Biotech (rated Overweight) - **Pharma**: Hansoh Pharma and Hengrui-A (rated Overweight) - **CXO**: WuXi Apptec and WuXi XDC (rated Overweight) - Caution is advised regarding Akeso due to unclear updates on HARMONi-2 OS [2][5][6]. Upcoming Events and Legislative Considerations - **NRDL Price Negotiations**: Anticipated results from the National Reimbursement Drug List (NRDL) price negotiations are expected to be neutral to negative, reflecting the current weak sentiment [5][6]. - **Biosecure Act**: The potential passing of the Biosecure Act could be a negative headline event, although it is not expected to significantly impact China CXOs' business [5][6]. - **Medical Conferences**: Upcoming medical conferences in December (e.g., ASH'25 and SABCS'25) are not expected to affect overall sentiment towards the China healthcare sector [5][6]. Emerging Themes for 2026 - Potential interest in new drug modalities such as **siRNA** (small interfering RNA) and **RDC** (radionuclide drug conjugate) is anticipated, along with expectations for global Phase 3 data from out-licensed assets [5][6]. - A healthy out-licensing deal flow is expected in 2026, although it may not surpass the total deal size of 2025 due to several significant deals this year [6]. - The **JPM Global Healthcare Conference** in January 2026 is expected to provide further insights into the prospects for the China healthcare sector, with presentations from over a dozen public and private Chinese companies [6]. Key Companies Discussed - **Akeso** (9926.HK) - **Hansoh Pharma** (3692.HK) - **Hengrui** (600276.SS) - **Innovent Biologics** (1801.HK) - **Kelun Biotech** (6990.HK) - **WuXi AppTec** (603259.SS and 2359.HK) - **WuXi XDC** (2268.HK) [8]. Conclusion - The China healthcare sector is currently facing challenges but presents potential investment opportunities as valuations become more attractive. Key themes and developments in 2026 will be closely monitored, particularly in light of upcoming conferences and legislative changes [2][5][6].

For more on the moves, Missouo healthcare strategist Jared Holes joins us here on set. Jared, great to have you with us. It felt like the bar was sort of low when it comes to Novo and the Alzheimer's data and yet the stock is moving this much lower.I mean, what what do you need to see at this point. What do I mean, is it a value trap here. I >> think you just need to see some resurrection of of its obesity drug in terms of revenue, right.Like it's hard to believe we're at four to five year lows with in the ...

Core Insights - Nanobiotix reported operational updates and financial results for Q3 2025, highlighting advancements in clinical programs and a significant financing milestone [1][3][4] Operational Highlights - The company completed a non-dilutive royalty financing transaction with HCRx valued up to $71 million, including an upfront payment of $50 million and an additional $21 million expected in one year [4][5][6] - Progress was made in the JNJ-1900 (NBTXR3) program, with the completion of the Phase 3 head and neck cancer study sponsorship transfer to Johnson & Johnson and initial data from a Phase 1 esophageal cancer study [3][4][5] - The Curadigm Nanoprimer program is emerging as a long-term growth driver, with new patent applications filed and pre-clinical data presented at industry conferences [5][6] Financial Updates - As of September 30, 2025, the company reported €20.4 million in cash and cash equivalents, with the recent financing expected to extend cash visibility into early 2028 [4][12] - The royalty financing will be repaid from a capped portion of milestones and royalties on sales of JNJ-1900, structured through a trust involving multiple parties [7] Clinical Development Outlook - Clinical updates from ongoing or completed studies of JNJ-1900 (NBTXR3) in various cancers, including melanoma, lung cancer, pancreatic cancer, and esophageal cancer, are expected in 2026 [4][8][12] - JNJ-1900 (NBTXR3) is being evaluated as a single agent and in combination therapies, with a focus on solid tumors treatable with radiotherapy [9][10][11]

Core Insights - Aura Biosciences, Inc. is a clinical-stage biotechnology company focused on developing precision therapies for solid tumors aimed at preserving organ function [3] - The CEO, Elisabet de los Pinos, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025 [1] - The company's lead candidate, bel-sar (AU-011), is in late-stage development for early choroidal melanoma and early-stage development for other ocular oncology indications and bladder cancer [3] Company Overview - Aura Biosciences is headquartered in Boston, MA, and aims to grow as an innovative global oncology company that positively transforms patients' lives [3] - The company provides a live webcast of events on its "Investors & Media" page, with replays available for 90 days [2] - Investor relations contact is Alex Dasalla, Head of Investor Relations and Corporate Communications [5]

Core Insights - Regeneron Pharmaceuticals is a leading biotechnology company focused on innovative treatments for serious diseases, competing with major players like Amgen and Biogen [1][5] - Truist Financial has set a price target of $798 for Regeneron, indicating a potential price increase of 4.11% from its current price of $766.50 [1][5] Stock Performance - Regeneron's stock is currently priced at $768.79, reflecting a 1.71% increase, or $12.89, from its previous value [2] - The stock has fluctuated between $757 and $773.13 today, indicating active investor interest [2] - Over the past year, the stock has reached a high of $800.99 and a low of $476.49, showcasing its growth potential and challenges faced [4] Market Capitalization and Trading Activity - Regeneron's market capitalization is approximately $79.4 billion, highlighting its significant presence in the biotech industry [3][5] - The trading volume today is 156,611 shares on the NASDAQ exchange, suggesting that investors are closely monitoring Regeneron's performance amid market volatility [3]

Market Overview - Recent market volatility has led to significant outflows, with 247 stocks sold, marking the highest outflows since April, affecting approximately 20% of the analyzed universe of 1,500 stocks [2] - The tech sector experienced notable selling, with 68 outflows, while discretionary and industrial sectors also saw significant declines [3] ETF and Crypto Impact - 40% of ETF outflows in the past 6 to 8 weeks have been related to cryptocurrency, indicating a broader deleveraging trend in the market [4] - The current sell-off is characterized by a correction in mega-cap tech stocks, which had previously been resilient [5] Investment Opportunities - Semiconductors have entered correction territory, presenting potential investment opportunities, particularly in companies like Broadcom and Lamb Research [9][10] - Meta has seen a 26% decline from its high, historically providing a good entry point for investors [10] Sector Analysis - The healthcare sector has shown overbought signals, suggesting caution for new investments despite its recent popularity [11][12] - The market is expected to recover, with potential for new highs by the end of the year, driven by continued earnings growth [13][14] Market Sentiment - Current market conditions indicate that only 31% of S&P constituents are above their 50-day moving average, suggesting room for upside potential [15]

Now for more on that healthc care space, let's bring in Evan Seager, the head of healthcare research over at Beimo Capital Markets. Evan, thank you very much for being here with us. Take us through the dynamic.I mean, GLP1s have been the focus for such a long time now. Is there anything that gets this competitive dynamic between Lily and Novo to close the gap a bit in the coming months and quarters. >> Well, first off, thank you for having me.And I think just today there's a lot of anticipation into this Al ...

Meanwhile, take a look at shares of Novo today falling to a four-year low this morning after results from its highly anticipated Alzheimer's drug trial failed to meet its main goal. The trial showed Novo's weight loss drug MGovi did not slow the progression of Alzheimer's. Joining us with some reaction today, city's head of US Pharma and biotech research Jeff Meum is with us.Jeff, thanks for the time. Good to see you again. >> Yeah, you too, Carl.Thank you for having me. >> I've seen the phrase longshot ass ...